Skip to main content
Premium Trial:

Request an Annual Quote

Cyntellect Nets $15.5M in New Financing

NEW YORK (GenomeWeb News) – Cytometry workstation products developer Cyntellect has raised $15.5 million in a financing round that could total $18.6 million, according to a filing with the US Securities and Exchange Commission.

The San Diego-based firm offers a core technology that uses microplate-based cytometry to analyze cells for use in diagnostics and therapeutics.

Cyntellect's Celigo cytometer provides a label-free assay for in situ cell counting of live cells by imaging every cell within all areas of multi-well plates and culture flasks, which Cyntellect says cuts out the need for estimation or for forcing the cells into suspension.

The firm did not name the investors involved in the financing round so far.

As GenomeWeb Daily News reported in October, the company has recently opened a European sales office in Newport, UK that will have sales, scientific and service staff in France, Germany, and the Netherlands, and will support the entire EU.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.